Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright
Oct 28, 2024
auto_awesome
Bill Enright, CEO of Barinthus Biotherapeutics, has a track record of taking on leadership roles during tumultuous times. He recounts how he turned around challenges at Altimmune during the 2008 financial crisis. Joining Barinthus before the COVID-19 pandemic, he made pivotal decisions that laid the foundation for future success. The conversation dives into innovations in immunotherapy targeting hepatitis B and celiac disease, as well as the importance of recognizing strategic opportunities in the ever-evolving biotech landscape.
Bill Enright's transition from science to business in biotech highlights the value of financial and marketing knowledge for career advancement.
His leadership during crises at Altimmune and Barinthus Biotherapeutics demonstrates the necessity of adaptability and strong team morale in overcoming challenges.
Deep dives
Career Transition in Biotech Management
Bill Enright's journey into the biopharmaceutical industry began at Life Technologies, where he discovered his interest in the business side of science while managing an incubator company. This experience prompted him to pursue a master's degree in business management at Johns Hopkins, enabling his transition from focus on scientific research to business development roles. He emphasizes the importance of gaining business acumen, suggesting that a grounding in finance and marketing can significantly aid those moving from science to executive positions in biotech. Enright's path reflects an opportunistic approach to career development, as he navigated various roles without a predetermined plan, showcasing the dynamic nature of career progression in the biotech sector.
Challenges and Perseverance During Economic Turmoil
During his tenure as CEO at Altimmune, Bill Enright faced significant challenges when he was recruited just before the 2008 financial crisis. This forced him to make tough decisions, including restructuring the organization and taking a year without salary to keep the company afloat. Despite the dire circumstances, he led the team through difficult times, utilizing a loan secured against his home and ensuring that employees would eventually be compensated for their sacrifices. His experience underscores the importance of perseverance and commitment in leadership, particularly in crisis situations, where maintaining team morale is crucial.
Navigating a Changing Landscape at Barinthus
Upon joining Barinthus Biotherapeutics in August 2019, Enright transitioned the company from an initial focus on flu vaccines to investigating COVID-19 vaccine opportunities, which quickly expanded following the onset of the pandemic. When the company's clinical trials did not yield successful data, he remained agile, pivoting resources towards promising areas such as hepatitis B and celiac disease. By collaborating with significant partners like AstraZeneca, Barinthus managed to secure non-dilutive funding and validate its platform during a tumultuous time. This adaptability not only aided the company during a global crisis but also laid a strong foundation for its core programs moving forward.
Strategic Focus and Future Directions
Bill Enright's leadership at Barinthus now centers on streamlining efforts towards high-potential programs in hepatitis B and celiac disease, prompted by data-driven decisions. After pausing less promising research, the company aims to push forward with phase two trials, capitalizing on favorable interim data and unique market opportunities. With a strong financial runway extending into 2026, Enright plans to leverage the differentiated therapeutic mechanisms being explored to address critical medical needs. His focus on refining strategic goals has positioned Barinthus to capitalize on emerging markets, ensuring that the company remains resilient and competitive in the biotech landscape.
It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn in great detail how Altimmune escaped that death knell. Later, he joined his current company, Barinthus Biotherapeutics, mere months before the Covid pandemic. That was shaky for a hot minute, but it turned out fortuitous when, against his better judgment, he enabled a pivot that became foundational to the company's go-forward plan. We'll learn how he flipped the script on that crisis, too. Tune in for these, and other harrowing tales from the trenches.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
